Last Updated : June 7, 2019
Details
Generic Name:
Trastuzumab
Project Status:
Cancelled
Manufacturer:
Pfizer Canada Inc.
Brand Name:
TBD
Project Line:
Reimbursement Review
Project Number:
PC0160-000
Tumour Type:
Breast & Gastrointestinal
Indications:
Breast and Gastric Cancer Biosimilar
Funding Request:
Breast and Gastric Cancer Biosimilar
Review Status:
Cancelled
Pre Noc Submission:
Yes
Sponsor:
Pfizer Canada Inc.
Submission Date (Target Date):
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : June 7, 2019